<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypersensitivity vasculitis in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypersensitivity vasculitis in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypersensitivity vasculitis in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Cabral, MBBS, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimberly Morishita, MD, MHSc, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Klein-Gitelman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "hypersensitivity vasculitis" has been used to refer to a vasculitis of small blood vessels of the skin that is secondary to an immune response or hypersensitivity reaction to an often unidentifiable exogenous substance. Names often used interchangeably with hypersensitivity vasculitis, but controversially, have included drug-induced vasculitis, cutaneous leukocytoclastic vasculitis, cutaneous small-vessel vasculitis, serum sickness, and allergic vasculitis [<a href="#rid1">1</a>]. The term "hypersensitivity vasculitis" was not included in the 2012 Chapel Hill Consensus Conference Nomenclature for systemic vasculitis [<a href="#rid2">2</a>] nor in its dermatologic addendum [<a href="#rid3">3</a>]. It is also not a named subtype of cutaneous vasculitis used in dermatology literature [<a href="#rid4">4</a>]. Hypersensitivity vasculitis, as traditionally classified [<a href="#rid5">5</a>], is best encompassed currently under the broad categories of either "single organ vasculitis" and named as cutaneous arteritis or cutaneous leukocytoclastic angiitis (eg, skin limited and without glomerulonephritis) [<a href="#rid2">2</a>] or alternatively under the category of "vasculitis associated with probable etiology" when there is an identifiable associated triggering agent or process (eg, infection, drug, or malignancy) [<a href="#rid2">2,3</a>]. (See  <a class="medical medical_review" href="/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a>.)</p><p>Hypersensitivity vasculitis in children, including the clinical features, diagnosis, and treatment that are reviewed here, primarily encompasses what is now more commonly described as either cutaneous leukocytoclastic vasculitis or drug- and infection-triggered vasculitis (eg, minocycline-associated vasculitis or hepatitis B-associated vasculitis). Cutaneous vasculitis as a paraneoplastic presentation is rare in children [<a href="#rid6">6</a>], but there are reports of leukemia-associated vasculitis [<a href="#rid7">7,8</a>].</p><p>Serum sickness and serum sickness-like reactions share clinical and pathologic features with hypersensitivity vasculitis; however, many cases do not have actual vascular inflammation. Serum sickness and serum sickness-like disorders are presented separately. (See  <a class="medical medical_review" href="/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a>.)</p><p>Urticarial vasculitis and hypocomplementemic urticarial vasculitis, usually with systemic manifestation, are also discussed separately. (See  <a class="medical medical_review" href="/d/html/8218.html" rel="external">"Urticarial vasculitis"</a>.)</p><p class="headingAnchor" id="H98462834"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>There are no pediatric-specific classification criteria for hypersensitivity vasculitis [<a href="#rid9">9</a>]. All available systems are based upon adult data. The most commonly used system is that of the American College of Rheumatology (ACR) [<a href="#rid5">5</a>] (see <a class="local">'Drugs'</a> below). Children were explicitly excluded when the ACR criteria were proposed in 1990 due to the lack of pediatric data. In the absence of clearly superior alternatives, the ACR criteria are nonetheless commonly used in children.</p><p>The ACR criteria for hypersensitivity vasculitis are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;16 years</p><p class="bulletIndent1"><span class="glyph">●</span>Use of a possible offending drug in temporal relation to the symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura</p><p class="bulletIndent1"><span class="glyph">●</span>Maculopapular rash</p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy of a skin lesion showing neutrophils around an arteriole or venule</p><p></p><p>The presence of three or more of these criteria has a sensitivity and specificity for the diagnosis of hypersensitivity vasculitis of 71 and 84 percent, respectively, among adults with known vasculitis [<a href="#rid5">5</a>]. These criteria do not distinguish hypersensitivity vasculitis from immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), with the latter characterized by palpable purpura and the deposition of IgA in the skin lesion [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Hypersensitivity vasculitis was first reported after the administration of heterologous antisera and was initially called serum sickness. In the past, serum sickness was the most frequent form of vasculitis because of the use of therapeutic antisera.</p><p>Hypersensitivity vasculitis is thought to represent an immune response to agents reacting as haptens and resulting in immune complex deposition. In most cases, the inciting antigen is never identified, and the disease remains idiopathic. In others, it may be caused by a specific drug or occur in association with an infection, malignancy, or other systemic disease.</p><p class="headingAnchor" id="H5"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Drugs are the most common identified cause of hypersensitivity vasculitis. Many medications can cause cutaneous vasculitis, but antibiotics (especially beta-lactams, sulfonamides), nonsteroidal antiinflammatory drugs, diuretics, anticonvulsants, and anti-tumor necrosis factor (TNF) biologic agents are often implicated as the inciting agents  (<a class="graphic graphic_table graphicRef81148" href="/d/graphic/81148.html" rel="external">table 1</a>) [<a href="#rid11">11-15</a>]. (See  <a class="medical medical_review" href="/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a>.)</p><p>Drug-induced vasculitis is a poorly defined disorder since proving causality is difficult. As a result, characterization of all suspected cases of drug-induced vasculitis should include [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Precipitating agent</p><p class="bulletIndent1"><span class="glyph">●</span>Involved organs (eg, isolated to the skin, gastrointestinal tract, etc)</p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic description</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Food</span><span class="headingEndMark"> — </span>There are rare reports of foods and food additives as potential triggers of hypersensitivity vasculitis in children [<a href="#rid16">16</a>]. As an example, in two reported cases, symptoms resolved after elimination of the suspected food antigen and recurred with reintroduction of the specific food (rechallenge) [<a href="#rid16">16</a>]. In one child, the offending agent was cow's milk and, in the other, chocolate and other cocoa-containing products.</p><p class="headingAnchor" id="H7"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Several infectious agents have been associated with hypersensitivity vasculitis, including hepatitis B or C, streptococcal agents, <em>Mycobacterium tuberculosis</em>, and human immunodeficiency virus (HIV) [<a href="#rid10">10,12,17</a>]. Hypersensitivity vasculitis has also been reported in patients with endocarditis and infected shunts [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H15036260"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Hypersensitivity vasculitis begins with deposition of soluble immune complexes that, together with immune reactants, are histologically identifiable in vessels early in the disease [<a href="#rid18">18</a>]. Immune complexes activate the classic and alternative complement pathways. The consequent mast cell degranulation, activation of neutrophils, release of cytokines and enzymes, and other processes in the cascade lead to tissue destruction and ultimately neutrophil phagocytosis (leukocytoclastic vasculitis) and removal of the immune complexes within 24 hours [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/3968.html" rel="external">"Complement pathways"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The hallmark of hypersensitivity vasculitis is the skin finding of palpable purpura and/or petechiae  (<a class="graphic graphic_picture graphicRef78697 graphicRef60323" href="/d/graphic/78697.html" rel="external">picture 1A-B</a>). Lesions most commonly occur in areas of decreased or slowed blood flow, particularly the lower extremities and other dependent areas, or under tight-fitting clothing. Edema may accompany some lesions. Other cutaneous manifestations of the vasculitis seen in some cases include macules, papules, ulcers, subcutaneous nodules, and urticaria.</p><p>In most patients, symptoms begin 7 to 10 days after antigen exposure, the time required to produce a sufficient quantity of primary antibody to form antigen-antibody complexes [<a href="#rid11">11</a>]. Symptoms may be delayed for two weeks or more in the case of longer-acting drugs, such as <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">benzathine penicillin</a>, while the latent period may be as short as two to seven days with a secondary exposure [<a href="#rid20">20</a>]. Manifestations usually appear abruptly. Skin lesions generally are at the same stage of development and typically resolve after a period of days to weeks. Postinflammatory pigmentation is common. Ulcerative or necrotic lesions may persist longer and leave residual scarring.</p><p>Additional findings may include [<a href="#rid10">10-12,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever</p><p class="bulletIndent1"><span class="glyph">●</span>Malaise</p><p class="bulletIndent1"><span class="glyph">●</span>Myalgias/arthralgias</p><p class="bulletIndent1"><span class="glyph">●</span>Arthritis</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphadenopathy</p><p></p><p>Despite the fact that skin lesions predominate, other organ systems may be involved to varying degrees. However, it is difficult to ascertain the frequency of noncutaneous organ involvement because of the lack of detailed description of internal organ involvement in most cases and a bias for reporting isolated cases with serious end-organ damage. In adult series, glomerulonephritis, interstitial nephritis, kidney impairment and varying degrees of hepatocellular injury have all been described [<a href="#rid12">12,15</a>]. Lung, heart, and central nervous system involvement are less commonly reported. (See  <a class="medical medical_review" href="/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a>.)</p><p>Although hypersensitivity vasculitis is usually acute and abates once the antigen has been cleared, prolonged disease may occur in conditions associated with chronic antigen exposure, such as persistent hepatitis B or C virus infection. Occasionally, chronic vasculitis may occur without an identifiable trigger. (See  <a class="medical medical_review" href="/d/html/3676.html" rel="external">"Extrahepatic manifestations of hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H15036514"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Although no specific laboratory test is diagnostic of hypersensitivity vasculitis, the following nonspecific findings are often seen in affected patients [<a href="#rid12">12,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild leukocytosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low serum complement levels, particularly C3 and C4, although there is no specific pattern of complement findings suggestive of the diagnosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated inflammatory markers, such as erythrocyte sedimentation and C-reactive protein</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive culture or serology (eg, hepatitis C virus) of an infectious agent associated with hypersensitivity vasculitis (see <a class="local">'Infection'</a> above and  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria, proteinuria, and cellular casts in patients with kidney involvement</p><p></p><p class="headingAnchor" id="H15036011"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Histopathology of palpable petechiae or purpura of the skin biopsied early in disease reveals prominent inflammation of the small blood vessels. Vessel walls and perivascular areas are infiltrated by neutrophils with resulting fibrinoid necrosis. This pattern is typically described as "leukocytoclastic vasculitis"  (<a class="graphic graphic_diagnosticimage graphicRef52548 graphicRef66296" href="/d/graphic/52548.html" rel="external">image 1A-B</a>), referring to the residual nuclear debris caused by the infiltrating neutrophils. In general, postcapillary venules are the most prominently involved vessels, with less frequent capillary and arteriole involvement. Drug-induced small vessel vasculitis is associated with a greater degree of tissue eosinophilia than non-drug-induced vasculitis [<a href="#rid21">21</a>].</p><p>The histologic pattern is highly sensitive to the age of the lesion. Lesions that are less than 24 hours old are most likely to demonstrate predominantly polymorphonuclear infiltration and other classic pathologic findings. Older lesions, on the other hand, show an increasing predominance of mononuclear cells as tissue repair supervenes.</p><p>In patients with kidney involvement, kidney biopsy, if performed, typically reveals a proliferative glomerulonephritis with immunoglobulin (primarily immunoglobulin G [IgG]) and complement deposition along the glomerular capillary wall.</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of hypersensitivity vasculitis is based upon clinical findings of palpable purpura and/or petechiae  (<a class="graphic graphic_picture graphicRef78697 graphicRef60323" href="/d/graphic/78697.html" rel="external">picture 1A-B</a>); a history of an offending agent, such as a drug or infection; a biopsied skin lesion that is characterized by a leukocytoclastic vasculitis  (<a class="graphic graphic_diagnosticimage graphicRef52548 graphicRef66296" href="/d/graphic/52548.html" rel="external">image 1A-B</a>) [<a href="#rid5">5</a>]; and exclusion of other systemic conditions that may present with similar disease manifestations. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In children, additional clinical criteria may be necessary to distinguish hypersensitivity vasculitis from the more commonly seen immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), such as IgA deposition that is seen in patients with IgAV (HSP), but not in those with hypersensitivity vasculitis.</p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Hypersensitivity vasculitis may be difficult to distinguish from other forms of vasculitis, particularly when findings are confined to the skin.</p><p class="headingAnchor" id="H15036669"><span class="h2">IgA vasculitis (Henoch-Schönlein purpura)</span><span class="headingEndMark"> — </span>Immunoglobulin A vasculitis (IgAV) is the most common disorder in the differential diagnosis of hypersensitivity vasculitis in children [<a href="#rid10">10,22</a>]. In both disorders, patients have leukocytoclastic vasculitis of small vessels. Palpable purpura and arthralgia are prominent features of IgAV. Additional features associated with IgAV include bowel angina, gastrointestinal bleeding, and/or hematuria. In contrast to patients with hypersensitivity vasculitis, patients with IgAV usually have normal complement levels and evidence of IgA-containing immune complexes on skin or kidney biopsy. An absence of recent use of medications that have the potential to cause vasculitis is also suggestive of the diagnosis of IgAV rather than hypersensitivity vasculitis. In practice, however, it may be difficult to distinguish between IgAV and hypersensitivity vasculitis, especially in the absence of these differentiating factors. (See  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H15036684"><span class="h2">Malignancy-associated vasculitis</span><span class="headingEndMark"> — </span>Malignancy-associated vasculitis is uncommon in children, but it has been reported [<a href="#rid7">7,8,23</a>]. Thus, patients who develop palpable purpura should be examined carefully for other signs or symptoms of a malignancy.</p><p class="headingAnchor" id="H15037400"><span class="h2">Systemic vasculitides</span><span class="headingEndMark"> — </span>Systemic vasculitides (eg, granulomatosis with polyangiitis, polyarteritis nodosa, and microscopic polyarteritis), although uncommon in children, may occasionally present with predominantly cutaneous involvement, such as palpable purpura. The presence of systemic signs and symptoms, evidence of major organ involvement, and antineutrophil cytoplasmic antibody (ANCA) positivity are helpful in identifying these syndromes and distinguishing them from hypersensitivity vasculitis [<a href="#rid2">2,9,12</a>]. Biopsy tissue showing pathologic lesions typical of these conditions, rather than immune complexes seen in hypersensitivity vasculitis, will usually confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a>.)</p><p class="headingAnchor" id="H15037407"><span class="h2">Other rheumatic diseases</span><span class="headingEndMark"> — </span>Vasculitis secondary to an underlying rheumatologic condition, such as systemic lupus erythematosus (SLE), juvenile idiopathic arthritis, juvenile dermatomyositis, or sarcoidosis, can rarely present with vasculitic skin rashes. In these conditions, there is not typically lower limb predominance. Once these diagnoses are considered, the child should be evaluated for distinguishing clinical features and laboratory findings of these conditions. (See  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6419.html" rel="external">"Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of patients with hypersensitivity vasculitis includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Removal of the inciting agent</strong> – Removal of the suspected inciting antigen (eg, discontinuation of the implicated drug) should lead to resolution of the lesions within a period of days to a few weeks. This supports the diagnosis [<a href="#rid13">13,15</a>].</p><p></p><p class="bulletIndent1">In patients with infection-associated hypersensitivity vasculitis, treatment should be aimed at the underlying infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic treatment</strong> – The disease often resolves spontaneously, without need for treatment when the vasculitis is mild and limited to the skin. Leg elevation, compression stockings, and simple analgesics may help with discomfort for lower limb disease, and antihistamines may help with associated itchiness. In patients with severe or persistent cutaneous disease, drugs such as <a class="drug drug_pediatric" data-topicid="13179" href="/d/drug information/13179.html" rel="external">colchicine</a>, antihistamines, nonsteroidal antiinflammatory drugs, and/or <a class="drug drug_pediatric" data-topicid="13205" href="/d/drug information/13205.html" rel="external">dapsone</a> may be helpful [<a href="#rid13">13,15,17</a>]. Immunosuppressive therapy with glucocorticoids or cytotoxic agents should be reserved for the infrequent patient with fulminant or progressive disease or with serious end-organ involvement [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/6403.html" rel="external">"Vasculitis in children: Management overview"</a>.)</p><p></p><p class="headingAnchor" id="H2181002541"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/579.html" rel="external">"Patient education: Vasculitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Hypersensitivity vasculitis refers to inflammation of small blood vessels of the skin. The process is caused by an immune response or hypersensitivity reaction to an exogenous substance, although the trigger is frequently not identifiable. (See <a class="local">'Introduction'</a> above and <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology and pathogenesis</strong> – Hypersensitivity vasculitis is thought to be caused by agents that act as haptens and stimulate an immune response. In some cases, the inciting antigen is an identifiable drug, infection, or, rarely, a malignancy. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Etiology'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings</strong> – The major clinical finding is cutaneous palpable purpura and/or petechiae  (<a class="graphic graphic_picture graphicRef78697 graphicRef60323" href="/d/graphic/78697.html" rel="external">picture 1A-B</a>). Biopsy of the lesions reveals prominent inflammation of the small blood vessels, typically with neutrophilic or mononuclear infiltration of the vessel wall and perivascular region, called leukocytoclastic vasculitis. Additional findings may include fever, malaise, myalgia, arthralgia/arthritis, lymphadenopathy, and kidney or liver disease. Rarely, vasculitis lesions may occur in the lung, heart, and central nervous system. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of hypersensitivity vasculitis is based upon clinical findings of palpable purpura and/or petechiae; the history of exposure to a potential inciting agent, such as a drug or infection; and a skin biopsy that demonstrates a leukocytoclastic vasculitis  (<a class="graphic graphic_diagnosticimage graphicRef52548 graphicRef66296" href="/d/graphic/52548.html" rel="external">image 1A-B</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – In children, immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) is the most common disorder in the differential diagnosis of hypersensitivity vasculitis. Normal complement levels and IgA deposition help to distinguish IgAV from hypersensitivity vasculitis. (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– The major intervention in the treatment of children with hypersensitivity vasculitis is removal of the inciting agent. Symptomatic therapy used in severe or persistent skin lesions includes <a class="drug drug_pediatric" data-topicid="13179" href="/d/drug information/13179.html" rel="external">colchicine</a>, antihistamines, nonsteroidal antiinflammatory drugs, and <a class="drug drug_pediatric" data-topicid="13205" href="/d/drug information/13205.html" rel="external">dapsone</a>. Immunosuppressive therapy with glucocorticoids or cytotoxic agents should be reserved for the infrequent patient with fulminant or progressive disease or other organ involvement. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H11881121"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Karyl S Barron, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Baigrie D, Bansal P, Goyal A, Crane JS. Leukocytoclastic vasculitis (hypersensitivity vasculitis). In: StatPearls [Internet], StatPearls Publishing, Treasure Island, FL 2020.</li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a class="nounderline abstract_t">Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018; 70:171.</a></li><li><a class="nounderline abstract_t">Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9:71.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108.</a></li><li><a class="nounderline abstract_t">Loricera J, Calvo-Río V, Ortiz-Sanjuán F, et al. The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Medicine (Baltimore) 2013; 92:331.</a></li><li><a class="nounderline abstract_t">Gupta A, Al Alenezi H, Ibrahim JM, Marouf R. Acute lymphoblastic leukaemia presenting as vasculitis. Br J Haematol 2006; 132:384.</a></li><li><a class="nounderline abstract_t">Jaing TH, Hsueh C, Chiu CH, et al. Cutaneous lymphocytic vasculitis as the presenting feature of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2002; 24:555.</a></li><li><a class="nounderline abstract_t">Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936.</a></li><li><a class="nounderline abstract_t">Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 1998; 77:403.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol 1996; 8:34.</a></li><li><a class="nounderline abstract_t">Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.</a></li><li><a class="nounderline abstract_t">Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med 2012; 70:12.</a></li><li><a class="nounderline abstract_t">ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36:130.</a></li><li><a class="nounderline abstract_t">Grau RG. Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects. Curr Rheumatol Rep 2015; 17:71.</a></li><li><a class="nounderline abstract_t">Businco L, Falconieri P, Bellioni-Businco B, Bahna SL. Severe food-induced vasculitis in two children. Pediatr Allergy Immunol 2002; 13:68.</a></li><li><a class="nounderline abstract_t">Sais G, Vidaller A, Jucglà A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 1995; 131:1399.</a></li><li><a class="nounderline abstract_t">Tosca N, Stratigos JD. Possible pathogenetic mechanisms in allergic cutaneous vasculitis. Int J Dermatol 1988; 27:291.</a></li><li><a class="nounderline abstract_t">Khetan P, Sethuraman G, Khaitan BK, et al. An aetiological &amp; clinicopathological study on cutaneous vasculitis. Indian J Med Res 2012; 135:107.</a></li><li><a class="nounderline abstract_t">Parker CW. Allergic reactions in man. Pharmacol Rev 1982; 34:85.</a></li><li><a class="nounderline abstract_t">Bahrami S, Malone JC, Webb KG, Callen JP. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 2006; 142:155.</a></li><li><a class="nounderline abstract_t">Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders. J Rheumatol 1992; 19:721.</a></li><li><a class="nounderline abstract_t">Funato M, Kaneko H, Kubota K, et al. Pediatric acute lymphoblastic leukemia mimicking Henoch-Schönlein purpura. Pediatr Int 2011; 53:766.</a></li></ol></div><div id="topicVersionRevision">Topic 6404 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Baigrie D, Bansal P, Goyal A, Crane JS. Leukocytoclastic vasculitis (hypersensitivity vasculitis). In: StatPearls [Internet], StatPearls Publishing, Treasure Island, FL 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045170" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29136340" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284262" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical approach to cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202309" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145696" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412013" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute lymphoblastic leukaemia presenting as vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12368694" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cutaneous lymphocytic vasculitis as the presenting feature of acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322081" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854604" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8867537" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Drug-induced vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217569" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical features and outcome of 95 patients with hypersensitivity vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271809" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Drug-induced vasculitis: a clinical and pathological review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11816242" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cutaneous and systemic manifestations of drug-induced vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26503355" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12000502" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Severe food-induced vasculitis in two children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492128" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3292447" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Possible pathogenetic mechanisms in allergic cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22382191" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : An aetiological&amp;clinicopathological study on cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7041144" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Allergic reactions in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490843" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1613701" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955011" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pediatric acute lymphoblastic leukemia mimicking Henoch-Schönlein purpura.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
